IOSP 10-Q Quarterly Report March 31, 2021 | Alphaminr
ALPHAMINR

IOSP 10-Q Quarter ended March 31, 2021

Balance Sheet
Cash Flow
Income Statement
Debt
INNOSPEC INC.
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-K
Fiscal year ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Sept. 30, 2011
10-Q
Quarter ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Sept. 30, 2010
10-Q
Quarter ended June 30, 2010
10-Q
Quarter ended March 31, 2010
10-K
Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on May 9, 2025
DEF 14A
Filed on March 27, 2025
DEF 14A
Filed on May 10, 2024
DEF 14A
Filed on March 28, 2024
DEF 14A
Filed on March 22, 2023
DEF 14A
Filed on May 4, 2022
DEF 14A
Filed on March 18, 2022
DEF 14A
Filed on March 19, 2021
DEF 14A
Filed on March 20, 2020
DEF 14A
Filed on March 22, 2019
DEF 14A
Filed on March 22, 2018
DEF 14A
Filed on March 17, 2017
DEF 14A
Filed on March 18, 2016
DEF 14A
Filed on March 20, 2015
DEF 14A
Filed on March 21, 2014
DEF 14A
Filed on March 22, 2013
DEF 14A
Filed on March 23, 2012
DEF 14A
Filed on April 1, 2011
DEF 14A
Filed on March 26, 2010
10-Q
Table of Contents
false 2020 Q1 --12-31 0001054905 DE 0001054905 2021-01-01 2021-03-31 0001054905 2020-01-01 2020-03-31 0001054905 2021-03-31 0001054905 2020-12-31 0001054905 2021-04-30 0001054905 2019-12-31 0001054905 2020-03-31 0001054905 iosp:SmithGambrellAndRussellLimitedLiabilityPartnershipMember 2021-03-31 0001054905 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2021-03-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2021-03-31 0001054905 iosp:AdvanSixMember 2021-03-31 0001054905 iosp:EuropeanMetalRecyclingLimitedMember 2021-03-31 0001054905 us-gaap:IntellectualPropertyMember 2021-03-31 0001054905 us-gaap:TrademarksAndTradeNamesMember 2021-03-31 0001054905 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-03-31 0001054905 us-gaap:CustomerRelationshipsMember 2021-03-31 0001054905 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-03-31 0001054905 iosp:ItalianTaxAuthoritiesMember 2021-03-31 0001054905 country:US 2021-03-31 0001054905 us-gaap:EmployeeStockOptionMember 2021-03-31 0001054905 iosp:StockEquivalentUnitsMember 2021-03-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member 2021-03-31 0001054905 iosp:UnrecognizedTaxBenefitsMember 2021-03-31 0001054905 iosp:InterestAndPenaltiesMember 2021-03-31 0001054905 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:EuropeMember 2021-03-31 0001054905 iosp:SmithGambrellAndRussellLimitedLiabilityPartnershipMember 2020-03-31 0001054905 iosp:UkPlanMember 2021-01-01 2021-03-31 0001054905 iosp:GermanPlanMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember iosp:RefineryAndPerformanceMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember iosp:OtherFuelSpecialtiesMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:PersonalCareMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:HomeCareMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:OtherPerformanceChemicalsMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember 2021-01-01 2021-03-31 0001054905 iosp:OilfieldServicesMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001054905 country:GB 2021-01-01 2021-03-31 0001054905 country:DE 2021-01-01 2021-03-31 0001054905 iosp:RemediationMember 2021-01-01 2021-03-31 0001054905 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember iosp:OtherNetIncomeExpenseMember 2021-01-01 2021-03-31 0001054905 us-gaap:NonUsMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-03-31 0001054905 us-gaap:NonUsMember us-gaap:LatestTaxYearMember 2021-01-01 2021-03-31 0001054905 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0001054905 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001054905 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001054905 iosp:StockEquivalentUnitsMember 2021-01-01 2021-03-31 0001054905 iosp:DiscountMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001054905 iosp:MarketValueMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001054905 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001054905 iosp:AdvanSixMember 2021-01-01 2021-03-31 0001054905 iosp:EuropeanMetalRecyclingLimitedMember 2021-01-01 2021-03-31 0001054905 iosp:UnrecognizedTaxBenefitsMember 2021-01-01 2021-03-31 0001054905 iosp:InterestAndPenaltiesMember 2021-01-01 2021-03-31 0001054905 iosp:OctaneAdditivesMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0001054905 us-gaap:SellingGeneralAndAdministrativeExpensesMember iosp:UkPlanMember 2021-01-01 2021-03-31 0001054905 country:DE us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001054905 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001054905 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001054905 srt:MaximumMember 2021-01-01 2021-03-31 0001054905 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-03-31 0001054905 us-gaap:NonUsMember iosp:HistoricalImpairmentOfSubsidiariesMember 2021-01-01 2021-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember iosp:RefineryAndPerformanceMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember iosp:OtherFuelSpecialtiesMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:FuelSpecialtiesMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:PersonalCareMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:HomeCareMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember iosp:OtherPerformanceChemicalsMember 2020-01-01 2020-03-31 0001054905 us-gaap:OperatingSegmentsMember iosp:PerformanceChemicalsMember 2020-01-01 2020-03-31 0001054905 iosp:OilfieldServicesMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001054905 country:GB 2020-01-01 2020-03-31 0001054905 country:DE 2020-01-01 2020-03-31 0001054905 iosp:RemediationMember 2020-01-01 2020-03-31 0001054905 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember iosp:OtherNetIncomeExpenseMember 2020-01-01 2020-03-31 0001054905 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0001054905 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001054905 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001054905 iosp:AdvanSixMember 2020-01-01 2020-03-31 0001054905 iosp:EuropeanMetalRecyclingLimitedMember 2020-01-01 2020-03-31 0001054905 iosp:OctaneAdditivesMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001054905 us-gaap:SellingGeneralAndAdministrativeExpensesMember iosp:UkPlanMember 2020-01-01 2020-03-31 0001054905 country:DE us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001054905 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001054905 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001054905 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001054905 iosp:StockEquivalentUnitsMember 2020-01-01 2020-03-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001054905 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001054905 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2020-12-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2020-12-31 0001054905 iosp:AdvanSixMember 2020-12-31 0001054905 iosp:SmithGambrellAndRussellLimitedLiabilityPartnershipMember 2020-12-31 0001054905 iosp:EuropeanMetalRecyclingLimitedMember 2020-12-31 0001054905 us-gaap:IntellectualPropertyMember 2020-12-31 0001054905 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001054905 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-12-31 0001054905 us-gaap:CustomerRelationshipsMember 2020-12-31 0001054905 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001054905 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001054905 us-gaap:SellingGeneralAndAdministrativeExpensesMember srt:EuropeMember 2020-12-31 0001054905 us-gaap:RevolvingCreditFacilityMember 2019-09-26 0001054905 us-gaap:RevolvingCreditFacilityMember iosp:AccordionFeatureMember 2019-09-26 0001054905 us-gaap:EmployeeStockOptionMember 2020-12-31 0001054905 iosp:StockEquivalentUnitsMember 2020-12-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001054905 us-gaap:CommonStockMember 2020-12-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001054905 us-gaap:TreasuryStockMember 2020-12-31 0001054905 us-gaap:RetainedEarningsMember 2020-12-31 0001054905 us-gaap:NoncontrollingInterestMember 2020-12-31 0001054905 iosp:UnrecognizedTaxBenefitsMember 2020-12-31 0001054905 iosp:InterestAndPenaltiesMember 2020-12-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001054905 us-gaap:CommonStockMember 2021-03-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001054905 us-gaap:TreasuryStockMember 2021-03-31 0001054905 us-gaap:RetainedEarningsMember 2021-03-31 0001054905 us-gaap:NoncontrollingInterestMember 2021-03-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001054905 us-gaap:CommonStockMember 2019-12-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001054905 us-gaap:TreasuryStockMember 2019-12-31 0001054905 us-gaap:RetainedEarningsMember 2019-12-31 0001054905 us-gaap:NoncontrollingInterestMember 2019-12-31 0001054905 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001054905 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001054905 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001054905 us-gaap:CommonStockMember 2020-03-31 0001054905 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001054905 us-gaap:TreasuryStockMember 2020-03-31 0001054905 us-gaap:RetainedEarningsMember 2020-03-31 0001054905 us-gaap:NoncontrollingInterestMember 2020-03-31 xbrli:shares iso4217:USD utr:Year iso4217:USD xbrli:shares
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
to
Commission file number
1-13879
INNOSPEC INC.
(Exact name of registrant as specified in its charter)
DELAWARE
98-0181725
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization
)
Identification No
.)
8310 South Valley Highway
Suite 350
Englewood
Colorado
80112
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone
num
ber
, including area code: ( 303 ) 792 5554
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common stock , par value $0.01 per share
IOSP
NASDAQ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such file. Yes ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated
filer 		☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class
Outstanding as of April 30, 2021
Common Stock, par value $0.01
24,608,245
Table of Contents
TABLE OF CONTENTS
PART I
2
Item 1
2
2
3
4
5
6
7
8
Item 2
20
20
20
26
Item 3
28
Item 4
29
PART II
30
Item 1
30
Item 1A
30
Item 2
30
Item 3
30
Item 4
30
Item 5
31
Item 6
31
32
Table of Contents
CAUTIONARY STATEMENT RELATIVE TO FORWARD-LOOKING STATEMENTS
This Form
10-Q
contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plan,” “intend” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, including, the effects of the
COVID-19
pandemic, such as its duration, its unknown long-term economic impact, measures taken by governmental authorities to address it and the manner in which the pandemic may precipitate or exacerbate other risks and/or uncertainties, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form
10-K
for the year ended December 31, 2020 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading “Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
1
PART I    FINANCIAL INFORMATION
Item 1    Condensed Consolidated Financial Statements
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three Months Ended
March 31
(in millions, except share and per share data)
2021
2020
Net sales
$ 339.6 $ 372.3
Cost of goods sold
( 238.8 ) ( 258.4 )
Gross profit
100.8 113.9
Operating expenses:
Selling, general and administrative
( 63.6 ) ( 64.4 )
Research and development
( 9.0 ) ( 8.6 )
Total operating expenses
( 72.6 ) ( 73.0 )
Operating income
28.2 40.9
Other income, net
3.0 3.9
Interest expense, net
( 0.4 ) ( 0.6 )
Income before income tax expense
30.8 44.2
Income tax expense
( 7.4 ) ( 11.1 )
Net income
$ 23.4 $ 33.1
Earnings per share:
Basic
$ 0.95 $ 1.35
Diluted
$ 0.94 $ 1.34
Weighted average shares outstanding (in thousands):
Basic
24,601 24,529
Diluted
24,840 24,742
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
2
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three Months Ended

March 31
(in millions)
2021
2020
Net income
$ 23.4 $ 33.1
Other comprehensive income/(loss):
Changes in cumulative translation adjustment, net of tax of $ 1.0 million and $ 1.6 million, respectively
( 11.3 ) ( 7.9 )
Amortization of prior service cost/(credit), net of tax of $ 0.0 and $ 0.0 million, respectively
0.1 ( 0.2 )
Amortization of actuarial net losses, net of tax of $( 0.1 ) million and $ 0.0 million, respectively
0.6 0.2
Total other comprehensive loss
( 10.6 ) ( 7.9 )
Total comprehensive income
$ 12.8 $ 25.2
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
3
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except share and per share data)
March 31,

2021
December 31,
2020
(Unaudited)
Assets
Current assets:
Cash and cash equivalents
$ 117.0 $ 105.3
Trade and other accounts receivable (less allowances of $ 4.1 million and $ 4.5 million respectively)
247.9 221.4
Inventories (less allowances of $ 19.4 million and $ 19.4 million respectively):
Finished goods
158.5 156.3
Raw materials
64.6 63.7
Total inventories
223.1 220.0
Prepaid expenses
12.3 14.9
Prepaid income taxes
5.0 4.2
Other current assets
2.3 0.4
Total current assets
607.6 566.2
Net property, plant and equipment
209.9 210.8
Operating lease
right-of-use
assets
36.7 40.1
Goodwill
367.2 371.2
Other intangible assets
70.2 75.3
Deferred tax assets
7.4 7.6
Pension asset
119.6 118.0
Other
non-current
assets
7.5 8.2
Total assets
$ 1,426.1 $ 1,397.4
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
4
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS - (Continued)
(in millions, except share and per share data)
March 31,
2021
December 31,
2020
(Unaudited)
Liabilities and Equity
Current liabilities:
Accounts payable
$ 114.5 $ 98.7
Accrued liabilities
131.8 129.8
Current portion of finance leases
0.4 0.5
Current portion of plant closure provisions
6.6 6.6
Current portion of accrued income taxes
8.8 5.5
Current portion of operating lease liabilities
12.2 11.3
Total current liabilities
274.3 252.4
Long-term debt
0.0 0.0
Finance leases, net of current portion
0.0 0.1
Operating lease liabilities, net of current portion
24.6 28.9
Plant closure provisions, net of current portion
51.3 51.9
Accrued income taxes, net of current portion
32.4 32.4
Unrecognized tax benefits
16.0 16.0
Deferred tax liabilities
46.5 46.9
Pension liabilities and post-employment benefits
19.5 20.5
Other
non-current
liabilities
2.4 3.4
Equity:
Common stock, $ 0.01 par value, authorized 40,000,000 shares, issued 29,554,500 shares
0.3 0.3
Additional
paid-in
capital
337.8 336.1
Treasury stock ( 4,946,360 and 4,958,599 shares at cost, respectively)
( 93.6 ) ( 93.3 )
Retained earnings
782.0 758.6
Accumulated other comprehensive loss
( 67.9 ) ( 57.3 )
Total Innospec stockholders’ equity
958.6 944.4
Non-controlling
interest
0.5 0.5
Total equity
959.1 944.9
Total liabilities and equity
$ 1,426.1 $ 1,397.4
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
5
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended

March 31
(in millions)
2021
2020
Cash Flows from Operating Activities
Net income
$ 23.4 $ 33.1
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
10.3 12.0
Deferred tax expense
0.1 0.7
Non-cash
movements on defined benefit pension plans
( 0.8 ) ( 1.2 )
Stock option compensation
1.6 1.2
Changes in assets and liabilities, net of effects of acquired and divested companies:
Trade and other accounts receivable
( 30.7 ) ( 7.9 )
Inventories
( 5.5 ) ( 5.0 )
Prepaid expenses
2.4 2.1
Accounts payable and accrued liabilities
20.2 ( 36.0 )
Accrued income taxes
3.7 1.6
Plant closure provisions
( 0.2 ) 0.1
Other assets and liabilities
( 1.8 ) 1.7
Net cash provided by operating activities
22.7 2.4
Cash Flows from Investing Activities
Capital expenditures
( 10.3 ) ( 7.8 )
Net cash used in investing activities
( 10.3 ) ( 7.8 )
Cash Flows from Financing Activities
Non-controlling
interest
0.0 0.1
Repayments of finance leases
( 0.2 ) ( 0.3 )
Issue of treasury stock
0.5 0.7
Repurchase of common stock
( 0.6 ) ( 2.1 )
Net cash used in financing activities
( 0.3 ) ( 1.6 )
Effect of foreign currency exchange rate changes on cash
( 0.4 ) ( 0.6 )
Net change in cash and cash equivalents
11.7 ( 7.6 )
Cash and cash equivalents at beginning of period
105.3 75.7
Cash and cash equivalents at end of period
$ 117.0 $ 68.1
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.
6
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)
(in millions)
Common

Stock
Additional

Paid-In

Capital
Treasury

Stock
Retained

Earnings
Accumulated

Other

Comprehensive

Loss
Non-

Controlling

Interest
Total

Equity
Balance at December 31, 2020
$ 0.3 $ 336.1 $ ( 93.3 ) $ 758.6 $ ( 57.3 ) $ 0.5 $ 944.9
Net income
23.4 23.4
Changes in cumulative translation adjustment, net of tax
( 11.3 ) ( 11.3 )
Treasury stock reissued
0.1 0.3 0.4
Treasury stock repurchased
( 0.6 ) ( 0.6 )
Stock option compensation
1.6 1.6
Amortization of prior service cost, net of tax
0.1 0.1
Amortization of actuarial net losses, net of tax
0.6 0.6
Balance at March 31, 2021
$ 0.3 $ 337.8 $ ( 93.6 ) $ 782.0 $ ( 67.9 ) $ 0.5 $ 959.1
(in millions)
Common

Stock
Additional

Paid-In

Capital
Treasury

Stock
Retained

Earnings
Accumulated

Other

Comprehensive

Loss
Non-

Controlling

Interest
Total

Equity
Balance at December 31, 2019
$ 0.3 $ 330.4 $ ( 93.3 ) $ 755.5 $ ( 74.4 ) $ 0.4 $ 918.9
Net income
33.1 33.1
Changes in cumulative translation adjustment, net of tax
( 7.9 ) ( 7.9 )
Share of net income
0.1 0.1
Treasury stock reissued
( 0.4 ) 1.4 1.0
Treasury stock repurchased
( 2.1 ) ( 2.1 )
Stock option compensation
1.2 1.2
Amortization of prior service credit, net of tax
( 0.2 ) ( 0.2 )
Amortization of actuarial net losses, net of tax
0.2 0.2
Balance at March 31, 2020
$ 0.3 $ 331.2 $ ( 94.0 ) $ 788.6 $ ( 82.3 ) $ 0.5 $ 944.3
The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements
7
Table of Contents
INNOSPEC INC. AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – BASIS OF PRESENTATION
The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form
10-Q
and Article 10 of Regulation
S-X
under the Securities Exchange Act of 1934. Accordingly, they do not include all the information and notes necessary for a comprehensive presentation of financial position, results of operations and cash flows.
It is our opinion, however, that all adjustments (consisting of normal, recurring adjustments, unless otherwise disclosed) have been made which are necessary for the condensed consolidated financial statements to be fairly stated. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form
10-K
for the year ended December 31, 2020 filed on February 17, 2021 (the “2020 Form
10-K”).
The results for the interim period covered by this report are not necessarily indicative of the results to be expected for the full year.
When we use the terms “Innospec,” “the Corporation,” “the Company,” “Registrant,” “we,” “us” and “our,” we are referring to Innospec Inc. and its consolidated subsidiaries unless otherwise indicated or the context otherwise requires.
NOTE 2 – SEGMENT REPORTING
The Company reports its financial performance based on the following three reportable segments: Fuel Specialties, Performance Chemicals and Oilfield Services.
The Fuel Specialties, Performance Chemicals and Oilfield Services segments operate in markets where we actively seek growth opportunities although their ultimate customers are different. Our previously reported Octane Additives segment ceased trading in the second quarter of 2020.
The Company evaluates the performance of its segments based on operating income. The following tables analyze sales and other financial information by the Company’s reportable segments:
Three Months Ended

March 31
(in millions)
2021
2020
Net Sales:
Refinery and Performance
$ 99.3 $ 108.6
Other
40.0 38.4
Fuel Specialties
139.3 147.0
Personal Care
68.2 63.0
Home Care
23.0 21.6
Other
34.7 28.5
Performance Chemicals
125.9 113.1
Oilfield Services
74.4 112.2
$ 339.6 $ 372.3
Gross profit/(loss):
Fuel Specialties
$ 44.9 $ 51.2
Performance Chemicals
31.4 27.6
Oilfield Services
24.5 36.2
Octane Additives
0.0 ( 1.1 )
$ 100.8 $ 113.9
Operating income/(loss):
Fuel Specialties
$ 23.8 $ 32.1
Performance Chemicals
18.3 15.6
Oilfield Services
1.2 7.2
Octane Additives
0.0 ( 1.2 )
Corporate costs
( 15.1 ) ( 12.8 )
Total operating income
$ 28.2 $ 40.9
8
Table of Contents
NOTE 3 – EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the effect of options that are dilutive and outstanding during the period under the treasury stock method. Per share amounts are computed as follows:
Three Months Ended
March 31
2021
2020
Numerator (in millions):
Net income available to common stockholders
$ 23.4 $ 33.1
Denominator (in thousands):
Weighted average common shares outstanding
24,601 24,529
Dilutive effect of stock options and awards
239 213
Denominator for diluted earnings per share
24,840 24,742
Net income per share, basic:
$ 0.95 $ 1.35
Net income per share, diluted:
$ 0.94 $ 1.34
In the three months ended March 31, 2021, the average number of anti-dilutive options excluded from the calculation of diluted earnings per share were 15,144 (three months ended March 31, 2020 – 17,636 ).
NOTE 4 – GOODWILL
The following table summarizes the goodwill movements:
(in millions)
Gross
Cost
Opening balance at January 1
$ 371.2
Exchange effect
( 4.0 )
Closing balance at March 31
$ 367.2
NOTE 5 – OTHER INTANGIBLE ASSETS
The following table summarizes the other intangible assets movements:
(in millions)
2021
Gross cost at January 1
$ 298.9
Exchange effec
t
( 2.0 )
Gross cost at March 31
296.9
Accumulated amortization at January 1
( 223.6 )
Amortization expense
( 4.0 )
Exchange effect
0.9
Accumulated amortization at March 31
( 226.7 )
Net book amount at March 31
$ 70.2
9
The amortization expense for the three months ended March 31, 2021 was $ 4.0 million (three months ended March 31, 2020 – $ 5.8 million).
The net book amount by category of other intangible assets is shown in the following table:
(in millions)
March 31

2021
December 31

2020
Product rights
$ 5.3 $ 6.3
Brand names
2.2 2.3
Technology
19.2 19.8
Customer relationships
41.2 44.2
Internally developed software
2.3 2.7
$ 70.2 $ 75.3
1
0
Table of Contents
NOTE 6 – PENSION AND POST EMPLOYMENT BENEFITS
The Company maintains a defined benefit pension plan (the “Plan”) covering a number of its current and former employees in the United Kingdom, although it does also have other much smaller pension arrangements in the U.S. and overseas. The Plan is closed to future service accrual but has a large number of deferred and current pensioners.
The net service cost for the three months ended March 31, 2021 was $ 0.4 million (three months ended March 31, 2020 – $ 0.3 million) and has been recognized in selling, general and administrative expenses within corporate costs. The following table shows the income statement effect recognized within other income, net:
Three Months Ended
March 31
(in millions)
2021
2020
Plan net pension credit/(charge):
Interest cost on projected benefit obligation
$ ( 1.9 ) $ ( 2.8 )
Expected return on plan assets
3.9 4.5
Amortization of prior service (cost)/credit
( 0.1 ) 0.2
Amortization of actuarial net losses
( 0.4 ) ( 0.2 )
$ 1.5 $ 1.7
The amortization of prior service credit and actuarial net losses is a reclassification out of accumulated other comprehensive loss into other income and expense.
The Company also maintains an unfunded defined benefit pension plan covering a number of its current and former employees in Germany (the “German plan”) within our Fuel Specialties segment. The German plan is closed to new entrants and has no assets. The net service cost for the German plan for the three months ended March 31, 2021 was $ 0.0 million (three months ended March 31, 2020 – $ 0.0 million) and has been recognized in selling, general and administrative expenses. The following table shows the income statement effect recognized within other income and expense:
Three Months Ended
March 31
(in millions)
2021
2020
Plan net pension charge:
Interest cost on projected benefit obligation
$ 0.0 $ 0.0
Amortization of actuarial net losses
( 0.3 ) ( 0.2 )
$
( 0.3
)
$
( 0.2
)
As at March 31, 2021, our Performance Chemicals segment has obligations for post-employment benefits in its European businesses with a liability of $ 5.1 million (December 31, 2020 – $ 5.3 million).
11
Table of Contents
NOTE 7 – INCOME TAXES
A roll-forward of unrecognized tax benefits and associated accrued interest and penalties is as follows:
(in millions)
Unrecognized
Tax Benefits
Interest and
Penalties
Total
Opening balance at January 1
$ 13.6 $ 2.4 $ 16.0
Net change for tax positions of prior periods
( 0.1 ) 0.1 0.0
Closing balance at March 31
13.5 2.5 16.0
Current
0.0 0.0 0.0
Non-current
$ 13.5 $ 2.5 $ 16.0
All of the $ 16.0 million of unrecognized tax benefits, interest and penalties would impact our effective tax rate if recognized.
As previously disclosed, a
non-U.S.
subsidiary, Innospec Performance Chemicals Italia Srl, is subject to an ongoing tax audit in relation to the period 2011 to 2014
inclusive. The C
ompany has determined additiona
l tax, interest and penalties totaling
$ 3.3 million may arise as a consequence of the tax audit. This includes a reduction for foreign exchange movements of $ 0.1 million recorded in the three months to March 31, 2021. As any additional tax arising as a consequence of the tax audit would be reimbursed by the previous owner under the terms of the sale and purchase agreement, an indemnification asset of the same amount is recorded in the financial statements to reflect this arrangement.
As previously disclosed, in 2018 the Company recorded an unrecognized tax benefit in relation to a potential adjustment that could arise as a consequence of the Tax Cuts and Jobs Act. The Company has determined that additional tax, interest and penalties totaling $ 12.5 million may arise in relation to this item. This includes an increase in interest accrued of $ 0.1 million in the three months to March 31, 2021.
Other non-significant items,
inclusive of interest and penalties, total $ 0.2 million.
The Company and its U.S. subsidiaries remain open to examination by the IRS for years 2017 onwards under the statute of limitations. The Company’s subsidiaries in foreign tax jurisdictions are open to examination including Germany (2016 onwards), Switzerland (2016 onwards), Spain (2016 onwards), France (2018 onwards) and the United Kingdom (2018 onwards).
12
Table of Contents
NOTE 8 – LONG-TERM DEBT
As at March 31, 2021, and December 31, 2020, the Company had repaid all of its borrowings under its revolving credit facility.
The Company continues to have available a $ 250.0 million revolving credit facility until September 25, 2024 . The facility contains an accordion feature whereby the Company may elect to increase the total available borrowings by an aggregate amount of up to $ 125.0 million.
The deferred finance costs of $ 1.3 million related to the arrangement of the credit facility, are included within other current and
non-current
assets at the balance sheet dates.
NOTE 9 – PLANT CLOSURE PROVISIONS
The Company has continuing plans to remediate some of its manufacturing facilities at sites around the world as and when those operations are expected to cease or we are required to decommission the sites according to local laws and regulations. The liability for estimated closure costs of Innospec’s manufacturing facilities includes costs for decontamination and environmental remediation activities (“remediation”).
As a result, the principal site giving rise to remediation liabilities is the manufacturing site at Ellesmere Port in the United Kingdom. There are also provisions on a much smaller scale in respect of some of our other manufacturing sites in the U.S. and Europe. We recognize environmental remediation liabilities when they are probable and costs can be reasonably estimated, and asset retirement obligations when there is a legal obligation and costs can be reasonably estimated.
Movements in the provisions are summarized as follows:
(in millions)
2021
Total at January 1
$ 58.5
Charge for the period
1.0
Utilized in the period
( 1.2 )
Exchange effect
( 0.4 )
Total at March 31
57.9
Due within one year
( 6.6 )
Due after one year
$ 51.3
The charge for the three months ended March 31, 2021 was $ 1.0 million (three months ended March 31, 2020 – $ 1.1 million).
The current and prior year charge represents the accounting accretion only, with no changes for the expected cost and scope of future remediation activities.
Amounts due within one year refer to provisions where expenditure is expected to arise within one year of the balance sheet date.
13
Table of Contents
NOTE 10 – FAIR VALUE MEASUREMENTS
The following table presents the carrying amount and fair values of the Company’s financial assets and liabilities measured on a recurring basis:
March 31, 2021
December 31, 2020
(in millions)
Carrying

Amount
Fair

Value
Carrying

Amount
Fair

Value
Assets
Non-derivatives:
Cash and cash equivalents
$ 117.0 $ 117.0 $ 105.3 $ 105.3
Derivatives (Level 1 measurement):
Other current and
non-current
assets:
Foreign currency forward exchange contracts
1.9 1.9 0.0 0.0
Liabilities
Non-derivatives:
Finance leases (including current portion)
0.4 0.4 0.6 0.6
Derivatives (Level 1 measurement):
Other current and
non-current
liabilities:
Foreign currency forward exchange contracts
0.0 0.0 0.5 0.5
Non-financial
liabilities (Level 3 measurement):
Other current and
non-current
liabilities:
Stock equivalent units
20.8 20.8 17.2 17.2
The following methods and assumptions were used to estimate the fair values:
Cash and cash equivalents:
The carrying amount approximates fair value because of the short-term maturities of such instruments.
Derivatives:
The fair value of derivatives relating to foreign currency forward exchange contracts are derived from current settlement prices and comparable contracts using current assumptions. Foreign currency forward exchange contracts primarily relate to contracts entered into to hedge future known transactions or hedge balance sheet net cash positions. The movements in the carrying amounts and fair values of these contracts are largely due to changes in exchange rates against the U.S. dollar.
Finance leases:
Finance leases relate to certain fixed assets in our Fuel Specialties and Oilfield Services segments. The carrying amount of finance leases approximates to the fair value.
Stock equivalent units:
The fair values of stock equivalent units are calculated at each balance sheet date using either the Black-Scholes or Monte Carlo method depending on the terms of each grant.
14
Table of Contents
NOTE 11 – DERIVATIVE INSTRUMENTS AND RISK MANAGEMENT
The Company enters into various foreign currency forward exchange contracts to minimize currency exchange rate exposure from expected future cash flows. As at March 31, 2021 the contracts have maturity dates of up to twelve months at the date of inception. These foreign currency forward exchange contracts have not been designated as hedging instruments, and their impact on the income statement for the first three months of 2021 was a gain of $ 1.3 million (first three months of 2020 – a gain of $ 1.9 million).
NOTE 12 – COMMITMENTS AND CONTINGENCIES
Legal matters
While we are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party, or of which any of their property is subject. It is possible, however, that an adverse resolution of an unexpectedly large number of such individual claims or proceedings could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.
Guarantees
The Company and certain of the Company’s consolidated subsidiaries are contingently liable for certain obligations of affiliated companies primarily in the form of guarantees of debt and performance under contracts entered into as a normal business practice. This includes guarantees of
non-U.S.
excise taxes and customs duties. As at March 31, 2021, such guarantees which are not recognized as liabilities in the condensed consolidated financial statements amounted to $ 8.1 million (December 31, 2020 - $ 9.9 million). The remaining terms of the fixed maturity guarantees are up to 3 years, with some further guarantees having no fixed expiry date.
Under the terms of the guarantee arrangements, generally the Company would be required to perform should the affiliated company fail to fulfil its obligations under the arrangements. In some cases, the guarantee arrangements have recourse provisions that would enable the Company to recover any payments made under the terms of the guarantees from securities held of the guaranteed parties’ assets.
The Company and its affiliates have numerous long-term sales and purchase commitments in their various business activities, which are expected to be fulfilled with no adverse consequences material to the Company.
15
Table of Contents
NOTE 13 – STOCK-BASED COMPENSATION PLANS
The Company grants stock options and stock equivalent units (“SEUs”) from time to time as a long-term performance incentive. In certain cases the grants are subject to performance conditions such as the Company’s stock price. Where performance conditions apply the Monte Carlo simulation model is used to determine the fair values. Otherwise the Black-Scholes model is used to determine the fair values.
Stock option plans
The following table summarizes the transactions of the Company’s stock option plans for the three months ended March 31, 2021.
Number of
Options
Weighted

Average

Exercise

Price
Weighted

Average

Grant-Date

Fair Value
Outstanding at December 31, 2020
442,893 $ 32.49 $ 45.31
Granted - at discount
69,996 $ 0.00 $ 92.32
- at market value
10,388 $ 99.85 $ 32.71
Exercised
( 18,493 ) $ 27.24 $ 37.03
Forfeited
( 1,307 ) $ 50.54 $ 32.61
Outstanding at March 31, 2021
503,477 $ 29.42 $ 51.97
At March 31, 2021, there were 115,847 stock options that were exercisable, of which 77,979 had performance conditions attached.
The stock option compensation cost for the first three months of 2021 was $ 1.6 million (first three months of 2020 – $ 1.2 million). The total intrinsic value of options exercised in the first three months of 2021 was $ 0.6 million (first three months of 2020 – $ 4.2 million).
The total compensation cost related to
non-vested
stock options not yet recognized at March 31, 2021 was $ 12.1 million and this cost is expected to be recognized over the weighted-average period of 2.22 years.
Stock equivalent units
The following table summarizes the transactions of the Company’s SEUs for the three months ended March 31, 2021:
Number

of SEUs
Weighted

Average

Exercise

Price
Weighted

Average

Grant-Date

Fair Value
Outstanding at December 31, 2020
390,164 $ 4.35 $ 63.96
Granted - at discount
87,451 $ 0.00 $ 88.94
- at market value
3,803 $ 99.85 $ 32.71
Exercised
( 6,275 ) $ 1.36 $ 42.82
Forfeited
( 12,400 ) $ 0.00 $ 67.33
Outstanding at March 31, 2021
462,743 $ 4.47 $ 68.62
1
6
Table of Contents
At March 31, 2021 there were 52,279 SEUs that are exercisable, of which 40,464 had performance conditions attached.
The charges for SEUs are spread over the life of the award subject to a revaluation to fair value each quarter. The revaluation may result in a charge or a credit to the income statement in the quarter dependent upon our share price and other performance criteria.
The SEU compensation for the first three months of 2021 was a $ 4.4 million
charge
(first three months of 2020 – $ 6.0 million credit). The total intrinsic value of SEUs exercised in the first three months of 2021 was $ 0.3 million (first three months of 2020 – $ 5.6 million).
The weighted-average remaining vesting period of
non-vested
SEUs is 2.26 years.
17
Table of Contents
NOTE 14 – RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE LOSS
Reclassifications out of accumulated other comprehensive loss for the first three months of 2021 were:
(in millions)
Details about AOCL Components
Amount
Reclassified
from AOCL
Affected Line Item in
the
Statement where
Net Income is
Presented
Defined benefit pension plan items:
Amortization of prior service credit
$ 0.1 See
(1)
below
Amortization of actuarial net losses
0.7 See
(1)
below
0.8 Total before tax
( 0.1 ) Income tax expense
Total reclassifications
$ 0.7 Net of tax
Reclassifications out of accumulated other comprehensive loss for the first quarter of 2020 were:
(in millions)
Details about AOCL Components
Amount
Reclassified
from
AOCL
Affected Line Item in
the Statement where
Net Income is
Presented
Defined benefit pension plan items:
Amortization of prior service credit
$ ( 0.2 ) See (¹) below
Amortization of actuarial net losses
0.2 See (¹) below
0.0 Total before tax
0.0 Income tax expense
Total reclassifications
$ 0.0 Net of tax
(1)
These items are included in other income and expense. See Note 6 of the Notes to the Condensed Consolidated Financial Statements for additional information.
Changes in accumulated other comprehensive loss for the first three months of 2021, net of tax, were:
(in millions)
Defined

Benefit

Pension

Plan Items
Cumulative
Translation
Adjustments
Total
Balance at December 31, 202
0
$ ( 15.9 ) $ ( 41.4 ) $ ( 57.3 )
Other comprehensive income before reclassifications
0.0 ( 11.3 ) ( 11.3 )
Amounts reclassified from AOCL
0.7 0.0 0.7
Total other comprehensive income
0.7 ( 11.3 ) ( 10.6 )
Balance at March 31, 2021
$ ( 15.2 ) $ ( 52.7 ) $ ( 67.9 )
Changes in accumulated other comprehensive loss for the first three months of 2020, net of tax, were:
(in millions)
Defined
Benefit
Pension Plan
Items
Cumulative
Translation
Adjustments
Total
Balance at December 31, 2019
$ ( 9.3 ) $ ( 65.1 ) $ ( 74.4 )
Other comprehensive income before
reclassification
s
0.0 ( 7.9 ) ( 7.9 )
Amounts reclassified from AOCL
0.0 0.0 0.0
Total other comprehensive income
0.0 ( 7.9 ) ( 7.9 )
Balance at March 31, 2020
$ ( 9.3 ) $ ( 73.0 ) $ ( 82.3 )
18
Table of Contents
NOTE 15 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
As previously reported, in December 2019 the Financial Accounting Standards Board issued Accounting Standards Update
(ASU) No. 2019-12, Simplifying
the Accounting for Income Taxes (Topic 740). This removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Adopting the new standard on January 1, 2021 has not impacted the Company’s prior period comparatives and will not have a material impact on the Company’s consolidated financial statements, including its accounting policies, processes and systems.
NOTE 16 – RELATED PARTY TRANSACTIONS
Mr. Patrick S. Williams has been an executive director of the Company since April 2009 and has been a
non-executive
director of AdvanSix, a chemicals manufacturer, since February 2020. In the first three months of 2021 the Company purchased product from AdvanSix for $ 0.0 million (first three months of 2020 – $ 0.1 million). As at March 31, 2021, the Company owed $ 0.0 million to AdvanSix (December 31, 2020 – $ 0.0 million).
Mr. Robert I. Paller has been a
non-executive
director of the Company since November 1, 2009. The Company has retained and continues to retain Smith, Gambrell & Russell, LLP (“SGR”), a law firm with which Mr. Paller holds a position. In the first three months of 2021 the Company incurred fees from SGR of $ 0.1 million (first three months of 2020 – $ 0.1 million). As at March 31, 2021, the Company owed $ 0.0 million to SGR (December 31, 2020 – $ 0.1 million).
Mr. David F. Landless has been a
non-executive
director of the Company since January 1, 2016 and is a
non-executive
director of Ausurus Group Limited which owns European Metal Recycling Limited (“EMR”). The Company has sold scrap metal to EMR in the first three months of 2021 for a value of $ 0.1 million (first three months of 2020 – $ 0.1 million). A tendering process is operated periodically to select the best buyer for the sale of scrap metal by the Company. As at March 31, 2021 EMR owed $ 0.0 million for scrap metal purchased from the Company (December 31, 2020 – $ 0.0 million).
19
Table of Contents
Item 2    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2021
This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes thereto.
CRITICAL ACCOUNTING ESTIMATES
The policies and estimates that the Company considers the most critical in terms of complexity and subjectivity of assessment are those related to environmental liabilities, pensions, income taxes, goodwill, property, plant and equipment and other intangible assets (net of depreciation and amortization) and the impact of the
COVID-19
pandemic (“the pandemic”) and the current economic environment. These policies have been discussed in the Company’s 2020 Form
10-K.
RESULTS OF OPERATIONS
The Company reports its financial performance based on the following three reportable segments: Fuel Specialties, Performance Chemicals and Oilfield Services. Our previously reported Octane Additives segment ceased trading in the second quarter of 2020.
The following table provides operating income by reporting segment:
Three Months Ended

March 31
(in millions)
2021
2020
Net sales:
Fuel Specialties
$
139.3
$
147.0
Performance Chemicals
125.9
113.1
Oilfield Services
74.4
112.2
$
339.6
$
372.3
Gross profit/(loss):
Fuel Specialties
$
44.9
$
51.2
Performance Chemicals
31.4
27.6
Oilfield Services
24.5
36.2
Octane Additives
0.0
(1.1
)
$
100.8
$
113.9
Operating income/(loss):
Fuel Specialties
$
23.8
$
32.1
Performance Chemicals
18.3
15.6
Oilfield Services
1.2
7.2
Octane Additives
0.0
(1.2
)
Corporate costs
(15.1
)
(12.8
)
Total operating income
$
28.2
$
40.9
20
Table of Contents
Three Months Ended March 31, 2021
The following table shows the change in components of operating income by reporting segment for the three months ended March 31, 2021 and the three months ended March 31, 2020:
Three Months Ended

March 31
(in millions, except ratios)
2021
2020
Change
Net sales:
Fuel Specialties
$ 139.3 $ 147.0 $ (7.7 ) -5 %
Performance Chemicals
125.9 113.1 12.8 +11 %
Oilfield Services
74.4 112.2 (37.8 ) -34 %
$ 339.6 $ 372.3 $ (32.7 ) -9 %
Gross profit:
Fuel Specialties
$ 44.9 $ 51.2 $ (6.3 ) -12 %
Performance Chemicals
31.4 27.6 3.8 +14 %
Oilfield Services
24.5 36.2 (11.7 ) -32 %
Octane Additives
0.0 (1.1 ) 1.1 -100 %
$ 100.8 $ 113.9 $ (13.1 ) -12 %
Gross margin (%):
Fuel Specialties
32.2
34.8
-2.6
Performance Chemicals
24.9
24.4
+0.5
Oilfield Services
32.9
32.3
+0.6
Aggregate
29.7
30.6
-0.9
Operating expenses:
Fuel Specialties
$ (21.1 ) $ (19.1 ) $ (2.0 ) +10 %
Performance Chemicals
(13.1 ) (12.0 ) (1.1 ) +9 %
Oilfield Services
(23.3 ) (29.0 ) 5.7 -20 %
Octane Additives
0.0 (0.1 ) 0.1 -100 %
Corporate costs
(15.1 ) (12.8 ) (2.3 ) +18 %
$ (72.6 ) $ (73.0 ) $ 0.4 -1 %
21
Table of Contents
Fuel Specialties
Net sales:
the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:
Three Months Ended March 31, 2021
Change (%)
Americas
EMEA
ASPAC
AvTel
Total
Volume
-2 -3 -2 -64 -7
Price and product mix
-4 -6 -2 +15 -3
Exchange rates
0 +12 +2 0 +5
-6 +3 -2 -49 -5
Volumes in all our regions have declined year over year, as the global demand for refined fuel products has not returned to
pre-pandemic
levels. The impact of the US winter storm and the Suez Canal blockage have had a negative impact on the anticipated return to a more normal level of economic activity. Price and product mix in all our regions was adverse due to higher sales of lower margin products. AvTel volumes were lower than the prior year due to variations in the demand from customers, being partly offset by a favorable price and product mix. EMEA and ASPAC benefitted from favorable exchange rate movements year over year, due to a strengthening of the British pound sterling and the European Union euro against the U.S. dollar.
Gross margin
: the year over year decrease of 2.6 percentage points was driven by higher sales of lower margin products, and is compared to a strong quarter in the prior year.
Operating expenses:
the year over year increase of $2.0 million was primarily due to higher share-based compensation accruals linked to the Innospec share price increase in the quarter, compared to lower accruals in the prior year due to the share price decline in the first quarter of 2020.
Performance Chemicals
Net sales:
the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:
Three Months Ended March 31, 2021
Change (%)
Americas
EMEA
ASPAC
Total
Volume
+16 +5 -10 +7
Price and product mix
+1 -3 -4 -2
Exchange rates
0 +9 +4 +6
+17 +11 -10 +11
Higher volumes in the Americas and EMEA were driven by increased demand for our Personal Care products, together with the recovery of demand in some of our other markets which have been adversely impacted by the pandemic. Volumes were lower in ASPAC primarily due to lower demand for our Personal Care products. The Americas benefitted from a favorable price and product mix due to increased sales of higher priced products. EMEA and ASPAC suffered an adverse price and product mix due to increased sales of lower priced products linked to lower raw material costs. EMEA and ASPAC benefitted from favorable exchange rate movements year over year, due to a strengthening of the British pound sterling and the European Union euro against the U.S. dollar.
22
Table of Contents
Gross margin:
the year over year increase of 0.5 percentage points was due to a richer sales mix and the timing of pricing movements for certain raw materials.
Operating expenses:
the year over year increase of $1.1 million was primarily due to higher share-based compensation accruals linked to the Innospec share price increase in the quarter, compared to lower accruals in the prior year due to the share price decline in the first quarter of 2020.
Oilfield Services
Net sales:
have decreased year over year by $37.8 million, or 34 percent. Customer demand has continued to grow sequentially quarter on quarter despite the US winter storm event which impacted certain oilfield activities during a two week period in February 2021. The Company has continued to see a sequential improvement in the demand for our products and services, which we expect to continue into the second quarter.
Gross margin:
the year over year increase of 0.6 percentage points was primarily due to a favorable sales mix and management cost control initiatives.
Operating expenses:
the year over year decrease of $5.7 million was driven by the continued
right-sizing
of the operations to adjust for the reduction in demand caused by the pandemic and lower acquired amortization. The decrease was partly offset by higher share-based compensation accruals linked to the Innospec share price increase in the quarter, compared to lower accruals in the prior year due to the share price decline in the first quarter of 2020.
Octane Additives
The Octane Additives business ceased trading and is no longer a reporting segment from July 1, 2020 as the production of TEL for use in motor gasoline has finished. Legacy costs related to these operations have now been recorded as operating expenses within corporate costs.
In the first three months of 2020, there was a gross loss of $1.1 million, together with operating expenses of $0.1 million.
Other Income Statement Captions
Corporate costs:
the year over year increase of $2.3 million was driven by higher share-based compensation accruals linked to the Innospec share price increase in the quarter, compared to lower accruals in the prior year due to the share price decline in the first quarter of 2020. There were also $0.8 million of acquisition related costs in the quarter, compared to none in the prior year.
23
Table of Contents
Other net income:
for the first quarter of 2021 and 2020, included the following:
(in millions)
2021
2020
Change
United Kingdom pension credit
$ 1.5 $ 1.7 (0.2 )
German pension charge
(0.3 ) (0.2 ) (0.1 )
Foreign exchange gain on translation
0.5 0.5 0.0
Foreign currency forward contracts gain
1.3 1.9 (0.6 )
$ 3.0 $ 3.9 $ (0.9 )
Interest expense, net:
was $0.4 million for the first quarter of 2021 compared to $0.6 million in the first quarter of 2020, driven by lower average net debt as the business generated cash inflows. Interest expense includes a commitment fee to retain the Company’s revolving credit facility, which was repaid in 2020.
Income taxes:
the effective tax rate was 24.0% and 25.1% in the first quarter of 2021 and 2020, respectively. The adjusted effective tax rate, once adjusted for the items set out in the following table, was 23.2% in 2021 compared with 25.1% in 2020. The 1.9 percentage points decrease in the adjusted effective rate was primarily due to the fact that a lower proportion of the Company’s profits are being generated in higher tax jurisdictions. The Company believes that this adjusted effective tax rate, a
non-GAAP
financial measure, provides useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, management uses this
non-GAAP
financial measure internally to evaluate the performance of the Company’s operations and for planning and forecasting in subsequent periods.
The following table shows a reconciliation of the GAAP effective tax rate to the adjusted effective tax rate:
Three Months Ended
March 31
(in millions)
2021
2020
Income before income taxes
$ 30.8 $ 44.2
Indemnification asset regarding tax audit
0.1 0.2
Adjustment for stock compensation
1.4 1.4
Acquisition costs
0.8 0.0
Legacy cost of closed operations
0.9 0.0
Adjusted income before income taxes
$ 34.0 $ 45.8
Income taxes
$ 7.4 $ 11.1
Tax on stock compensation
0.1 0.4
Adjustment of income tax provision
0.0 0.0
Tax on acquisition costs
0.2 0.0
Tax on legacy cost of closed operations
0.2 0.0
Adjusted income taxes
$ 7.9 $ 11.5
GAAP effective tax rate
24.0 % 25.1 %
Adjusted effective tax rate
23.2 % 25.1 %
24
Table of Contents
Changes in tax laws and rates may affect recorded tax assets and liabilities and our effective tax rate in the future. In March 2021, it was announced that the UK rate of corporation tax would increase from 19% to 25% from April 1, 2023, but the legislation accompanying this announcement was not enacted as at March 31, 2021.
Because a change in tax law is accounted for in the period of enactment, the effect of this change cannot be recognized in our financial results for the quarter ended March 31, 2021. Notwithstanding, we estimate that a charge of approximately $7.3 million will arise in the period of enactment reflecting the impact of the increase in the UK corporation tax rate on our UK deferred tax balances, and this will be accounted for as a discrete item. However, the impact will depend on a number of uncertainties regarding the Company’s assets and liabilities at the date on which the change in rate takes effect, such as the surplus/deficit on its UK defined benefit pension scheme at that time.
25
Table of Contents
LIQUIDITY AND FINANCIAL CONDITION
Working Capital
In the first three months of 2021 our working capital increased by $19.5 million, while our adjusted working capital increased by $9.2 million. The difference is primarily due to the exclusion of the increase in our cash and cash equivalents.
The Company believes that adjusted working capital, a
non-GAAP
financial measure, (defined by the Company as trade and other accounts receivable, inventories, prepaid expenses, accounts payable and accrued liabilities rather than total current assets less total current liabilities) provides useful information to investors in evaluating the Company’s underlying performance and identifying operating trends. Management uses this
non-GAAP
financial measure internally to allocate resources and evaluate the performance of the Company’s operations. Items excluded from working capital in the adjusted working capital calculation are listed in the table below and represent factors which do not fluctuate in line with the day to day working capital needs of the business.
(in millions)
March 31,

2021
December 31,
2020
Total current assets
$ 607.6 $ 566.2
Total current liabilities
(274.3 ) (252.4 )
Working capital
333.3 313.8
Less cash and cash equivalents
(117.0 ) (105.3 )
Less prepaid income taxes
(5.0 ) (4.2 )
Less other current assets
(2.3 ) (0.4 )
Add back current portion of accrued income taxes
8.8 5.5
Add back current portion of finance leases
0.4 0.5
Add back current portion of plant closure provisions
6.6 6.6
Add back current portion of operating lease liabilities
12.2 11.3
Adjusted working capital
$ 237.0 $ 227.8
We had a $26.5 million increase in trade and other accounts receivable, driven by the recovery of sales in all our segments due to the easing of the pandemic restrictions. Days’ sales outstanding in our Fuel Specialties segment has increased from 52 days to 54 days; increased in our Performance Chemicals segment from 60 days to 63 days; and increased from 63 days to 66 days in our Oilfield Services segment.
We had a $3.1 million increase in inventories as we managed inventory levels
in-line
with the demand recovery. Days’ sales in inventory in our Fuel Specialties segment decreased from 117 days to 112 days; decreased in our Performance Chemicals segment from 58 days to 56 days; and decreased from 95 days to 82 days in our Oilfield Services segment.
Prepaid expenses decreased $2.6 million, from $14.9 million to $12.3 million due to the normal expensing of prepaid costs.
We had a $17.8 million increase in accounts payable and accrued liabilities primarily due to higher production activity resulting from the recovery of customer demand. Creditor days (including goods received not invoiced) in our Fuel Specialties segment increased from 34 days to 40 days; increased in our Performance Chemicals segment from 48 days to 51 days; and decreased from 49 days to 47 days in our Oilfield Services segment.
26
Table of Contents
Operating Cash Flows
We generated cash from operating activities of $22.7 million in the first three months of 2021 compared to cash inflows of $2.4 million in the first three months of 2020. The year over year increase in the cash generated from our operating activities was primarily related to the effective control of our working capital in the current quarter, as the pandemic recovery supported the increased demand from our customers, compared to the adverse impact of the pandemic in the first quarter of 2020.
Cash
At March 31, 2021 and December 31, 2020, we had cash and cash equivalents of $117.0 million and $105.3 million, respectively, of which $65.8 million and $52.5 million, respectively, were held by
non-U.S.
subsidiaries principally in the United Kingdom.
The $11.7 million increase in cash and cash equivalents for the first three months of 2021, is primarily due to effective control of working capital as our customer demand has been recovering from the pandemic decline in 2020.
Debt
At March 31, 2021, we had no debt outstanding under the revolving credit facility and $0.4 million of obligations under finance leases relating to certain fixed assets within our Fuel Specialties and Oilfield Services segments.
At December 31, 2020, we had no debt outstanding under the revolving credit facility and $0.6 million of obligations under finance leases relating to certain fixed assets within our Fuel Specialties and Oilfield Services segments.
27
Table of Contents
Item 3    Quantitative and Qualitative Disclosures about Market Risk
The Company uses floating rate debt to finance its global operations. The Company is subject to business risks inherent in
non-U.S.
activities, including political and economic uncertainty, import and export limitations, and market risk related to changes in interest rates and foreign currency exchange rates. The political and economic risks are mitigated by the stability of the major countries in which the Company’s largest operations are located. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize bad debt risk. Collateral is not generally required.
From time to time, the Company uses derivatives, including interest rate swaps, commodity swaps and foreign currency forward exchange contracts, in the normal course of business to manage market risks. The derivatives used in hedging activities are considered risk management tools and are not used for trading purposes. In addition, the Company enters into derivative instruments with a diversified group of major financial institutions in order to manage the exposure to
non-performance
of such instruments. The Company’s objective in managing the exposure to changes in interest rates is to limit the impact of such changes on earnings and cash flows and to lower overall borrowing costs. The Company’s objective in managing the exposure to changes in foreign currency exchange rates is to reduce volatility on earnings and cash flows associated with such changes.
The Company offers fixed prices for some long-term sales contracts. As manufacturing and raw material costs are subject to variability the Company, from time to time, uses commodity swaps to hedge the cost of some raw materials thus reducing volatility on earnings and cash flows. The derivatives are considered risk management tools and are not used for trading purposes. The Company’s objective is to manage its exposure to fluctuating costs of raw materials.
The Company’s exposure to market risk has been discussed in the Company’s 2020 Annual Report on Form
10-K
and there have been no significant changes since that time.
28
Table of Contents
Item 4    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Based on an evaluation carried out as of the end of the period covered by this report, under the supervision and with the participation of our management, our Chief Executive Officer and our Chief Financial Officer concluded that the Company’s “disclosure controls and procedures” (as defined in Rules
13a-15(e)
and
15d-15(e)
of the Securities Exchange Act of 1934) were effective as of March 31, 2021.
Changes in Internal Control over Financial Reporting
The Company is continuously seeking to improve the efficiency and effectiveness of its operations and of its internal control over financial reporting. This is intended to result in refinements to processes throughout the Company.
There were no changes to our internal control over financial reporting which were identified in connection with the evaluation required by paragraph (d) of Rules
13a-15
and
15d-15
under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
29
Table of Contents
PART II    OTHER INFORMATION
Item 1    Legal Proceedings
Legal matters
While we are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims, there are no material pending legal proceedings to which the Company or any of its subsidiaries is a party, or of which any of their property is subject. It is possible, however, that an adverse resolution of an unexpectedly large number of such individual claims or proceedings could, in the aggregate, have a material adverse effect on results of operations for a particular year or quarter.
Item 1A    Risk Factors
Information regarding risk factors that could have a material impact on our results of operations or financial condition are described under “Risk Factors” in Item 1A of Part I of our 2020 Form
10-K.
In management’s view, there have been no material changes in the risk factors facing the Company since that time.
Item 2    Unregistered Sales of Equity Securities and Use of Proceeds
There have been no unregistered sales of equity securities.
During the quarter ended March 31, 2021 the Company made no open market repurchases of its common stock.
During the quarter ended March 31, 2021, the Company purchased its common stock in connection with the exercising of stock options by employees. The following table provides information about our repurchases of equity securities in the period.
Issuer Purchases of Equity Securities
Period
Total number

of shares

purchased
Average price

paid per share
February 1, 2021 through February 28, 2021
462 $ 97.37
March 1, 2021 through March 31, 2021
5,601 $ 103.25
Total
6,063 $ 102.80
Item 3    Defaults Upon Senior Securities
None.
Item 4    Mine Safety Disclosures
Not applicable.
30
Table of Contents
Item 5    Other Information
None.
Item 6    Exhibits
31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 XBRL Instance Document and Related Item - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
104 Cover Page Interactive Data File – The cover page XBRL tags are embedded within the inline XBRL document.
31
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INNOSPEC INC.
Registrant
Date: May 5, 2021 By
/s/                             PATRICK S. WILLIAMS
Patrick S. Williams
President and Chief Executive Officer
Date: May 5, 2021 By
/s/                             IAN P. CLEMINSON
Ian P. Cleminson
Executive Vice President and Chief Financial Officer
32
TABLE OF CONTENTS